Indaptus Therapeutics (NASDAQ:INDP) Issues Quarterly Earnings Results, Beats Expectations By $1.64 EPS

Indaptus Therapeutics (NASDAQ:INDP) announced its earnings results on Friday. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.87) by $1.64, Zacks reports.

Indaptus Therapeutics Stock Down 9.1%

INDP traded down $0.16 during midday trading on Friday, reaching $1.59. 82,975 shares of the company’s stock were exchanged, compared to its average volume of 64,398. The firm has a market capitalization of $3.56 million, a price-to-earnings ratio of -0.07 and a beta of 1.37. Indaptus Therapeutics has a one year low of $1.51 and a one year high of $19.91. The business has a 50-day simple moving average of $2.16 and a two-hundred day simple moving average of $2.33.

Institutional Investors Weigh In On Indaptus Therapeutics

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC acquired a new position in Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 1.72% of Indaptus Therapeutics as of its most recent SEC filing. 7.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.